Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pasithea Therapeutics (KTTA) Capital Expenditures (2021 - 2023)

Historic Capital Expenditures for Pasithea Therapeutics (KTTA) over the last 3 years, with Q4 2023 value amounting to -$36.0.

  • Pasithea Therapeutics' Capital Expenditures fell 10003.88% to -$36.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $34301.0, marking a year-over-year decrease of 6797.32%. This contributed to the annual value of $34301.0 for FY2023, which is 6797.32% down from last year.
  • Pasithea Therapeutics' Capital Expenditures amounted to -$36.0 in Q4 2023, which was down 10003.88% from -$22659.0 recorded in Q3 2023.
  • Pasithea Therapeutics' Capital Expenditures' 5-year high stood at $92725.0 during Q4 2022, with a 5-year trough of -$22659.0 in Q3 2023.
  • In the last 3 years, Pasithea Therapeutics' Capital Expenditures had a median value of $5486.0 in 2022 and averaged $17148.3.
  • Examining YoY changes over the last 5 years, Pasithea Therapeutics' Capital Expenditures showed a top increase of 266207.07% in 2023 and a maximum decrease of 51303.32% in 2023.
  • Over the past 3 years, Pasithea Therapeutics' Capital Expenditures (Quarter) stood at $12933.0 in 2021, then surged by 616.96% to $92725.0 in 2022, then crashed by 100.04% to -$36.0 in 2023.
  • Its last three reported values are -$36.0 in Q4 2023, -$22659.0 for Q3 2023, and $3108.0 during Q2 2023.